CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF and Biological Valve Prosthesis.

Raphael Philippart,Anne Brunet-Bernard,Nicolas Clementy,Thierry Bourguignon,Alain Mirza,Denis Angoulvant,Dominique Babuty,Gregory Y.H. Lip,Laurent Fauchier

CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF and Biological Valve Prosthesis.

2016

Raphael Philippart
Anne Brunet-Bernard
Nicolas Clementy
Thierry Bourguignon
Alain Mirza
Denis Angoulvant
Dominique Babuty
Gregory Y.H. Lip
Laurent Fauchier

Patients with valvular atrial fibrillation (AF), as defined in the 2012 European Society of Cardiology guidelines (those with a valvular prosthesis or rheumatic mitral disease) should receive anticoagulation regardless of the CHA2DS2-VASc score, with vitamin K antagonist being recommended [(1–3)][

Keywords:

Diabetes mellitus
Research design
Prosthesis
Atrial fibrillation
Risk assessment
Cardiology
Internal medicine
Vitamin K antagonist
Medicine
CHA2DS2–VASc score
Stroke
Surgery
in patient
valve prosthesis
valvular prosthesis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations